Fed Up Of Poorly Run Academic Spin-Outs? Try This Instead

Three big pharma and three major UK universities are working together to "find, fund and run academic drug discovery projects at a pharma quality level." The collaboration has had a productive first year with four programs underway, two more about to be finalized, and "a good flow" in the pipeline, according to CEO Dr Richard Butt.

Apollo Therapeutics LLC, a collaborative venture between AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, University College London and the University of Cambridge, was set up in January 2016.

The "fundamental difference" between Apollo and similar initiatives is the choosing of the projects "independent of what the pharma partners...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By 

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency

 
• By 

Restructuring Edition: Karyopharm is reducing its workforce by 20% as it seeks alternatives to extend its cash runway, but Pacira’s production improvements created efficiency that necessitate an 8% layoff in manufacturing. Jasper, Century, Sage, Leap and Prothena also cut jobs.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.